Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

148 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-04-27

Study Completion Date

2019-04-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to evaluate the endoplasmic reticulum stress markers as predictive for response to hydroxyurea in polycythemia vera (PV) and essential thrombocythemia (ET).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis.

NCT05440838

Myeloproliferative Neoplasm

NOT_YET_RECRUITING

Iron Overload and Transient Elastography in Patients With Myelodysplastic Syndrome

NCT02262312

Myelodysplastic Syndrome

COMPLETED

Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)

NCT02252159

MPN (Myeloproliferative Neoplasms)

COMPLETED

Genomic Screening for Hereditary Erythrocytosis and Related Diseases

NCT03263364

Hereditary Erythrocytosis/Idiopathic Erythrocytosis

UNKNOWN

Clinical and Laboratory Characteristics of Polycythemia Vera

NCT06134102

Polycythemia Vera

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The recent discovery of calreticulin mutations in myeloproliferative neoplasms point to the unexpected role of the endoplasmic reticulum biology in the pathophysiology in these diseases. Otherwise, the association of endoplasmic reticulum stress with solid cancers, in particular in resistance to chemotherapy, is well documented, contrary to hematological malignancies. The study aims to evaluate endoplasmic reticulum stress markers as predictors for the response to hydroxyurea in polycythemia vera and essential thrombocythemia patients. The main objective is to correlate endoplasmic reticulum stress (defined as splicing of XBP1 above 30%) to the rate of complete response after 6 months according to the 2009 ELN criteria. This is an observational retrospective study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Polycythemia Vera Essential Thrombocythemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients

ET or PV patients diagnosed before acceleration phase and treated by hydroxyurea with a follow up period of at least 6 months following treatment start, with a RNA sample of total leukocytes before start of treatment available

RNA sample of total leukocytes before start of treatment

Intervention Type BIOLOGICAL

RNA sample of total leukocytes before start of treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RNA sample of total leukocytes before start of treatment

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ET or PV patients diagnosed before acceleration phase and treated by hydroxyurea with a follow up period of at least 6 months following treatment start.
* Diagnosis criteria of PV :

* WHO criteria of PV with :

* Acquired JAK2V617F mutation \> 5%
* Absence of evident cause of secondary polycythemia
* Diagnosis criteria of ET :

* Platelet count \> 450 G/L
* Absence of PV or Chronic Myeloid Leukemia
* Bone marrow biopsy preferred but not necessary in absence of reactional causes (CRP and ferritin levels normal) and/or presence of acquired JAK2V617F, CALR exon 9 or MPL exon 10
* Availability of RNA sample of total leukocytes before start of treatment.

Exclusion Criteria

In absence of clonality marker, presence of secondary cause of :

* Thrombocytosis :

* Inflammatory syndrom (CRP or SV increased)
* Iron deficiency (decreased ferritin level or increased soluble transferrin receptor level)
* Polycythemia :

* Increased or normal level of EPO in context of :

* Hypoxia, respiratory insufficiency
* Sleep apnea syndrome
* Hyperaffin hemoglobin
* Absence of treatment by hydroxyurea
* Treatment by anagrelide, P32, pipobroman, interferon without subsequent hydroxyurea treatment.
* Concommitant treatment by other cancer chemotherapy (in a context of solid cancer for example).
* Diagnostic during transformation to acute leukemia
* Treatment by hydroxyurea during less than 6 months
* Bad observance of the cytotoxic treatment

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No